Better decisions
Connected development
PhaseV brings advanced statistical, causal, and simulation methods, and AI-assisted workflows into one clinical development platform, so teams can reduce avoidable risk, rework and delays
The problem
Decisions are connected
Tools rarely are
The population you choose shapes the trial design. The design determines where the trial can run. Each approved choice then flows into sites, data, analyses, and documents, and every program competes with others for the same budget and resources. Yet these decisions are usually made in separate tools, by separate teams and vendors, through manual handoffs. Context gets lost, work gets redone, and the cost shows up as delay, avoidable risk, and decisions made on partial information.
Why PhaseV
Built differently for clinical development
PhaseV combines the rigor of clinical and statistical expertise with purpose-built, modular software, explainable modeling, and a fit-for-purpose partnership model.
Tech + Clinical domain expertise
Clinical development is not only a software or data-engineering problem. PhaseV combines clinical-trial expertise with statistics, causal inference, machine learning, simulation, optimization, and software engineering.
Modular by design Connect by context
Start with one analysis or workflow. Add capabilities, evidence sources, and integrations when useful, without introducing another disconnected system or forcing a full-platform implementation.
Built around how your team works
PhaseV complements sponsor teams, CROs, and existing systems. Models, dashboards, governance, integrations, deployment, and operating workflows can be configured around the organization rather than a fixed template.
Case studies
See what better decisions can change
Explore anonymized examples across patient strategy, trial design, site strategy, and portfolio decisions.
Oncology
How smarter site selection saved a Phase 3 lung cancer trial 9 months and $30M
A Phase 3 lung cancer trial was set to miss its 24-month goal. Smarter sites and design cut 9 months, 33 sites and 95 patients.
Read the case →
Metabolic
Rescuing a failed Phase III trial: finding the patients who respond to oral insulin
After a Phase III oral insulin trial missed its endpoint, causal ML found the responder subgroups. Oramed re-initiated a Phase III trial.
Read the case →
Metabolic
What causal analysis revealed about weight loss and obesity-related disease
Causal analysis showed benefit appears only at very high weight loss and split weight-driven from direct drug effects.
Read the case →
Testimonials
What our partners are saying
“This was an amazing collaboration between Enlivex and PhaseV leading to the identification of a higher-responder group to our drug Allocetra in Knee osteoarthritis patients. Amazing team, smart, innovative, dedicated, responsive and pleasant.”
Oren Hershkovitz, Ph.D.
“We worked with PhaseV on one of our recent trials to identify clinically meaningful subgroups using Response Optimizer. Their expertise helped us identify a promising subpopulation that otherwise would not have been detected. They collaborated with our internal teams to ensure the findings drove real value for our development plan.”
Stu Bailey, D.Phil.
“Leveraging PhaseV’s ClinOps Optimizer was a game-changer for us. We identified top-performing sites with proven recruitment success while also achieving geographic and demographic diversity across our trial footprint.”
VP, Clinical Operations
“PhaseV’s Portfolio Optimizer helped us uncover and validate new indications to pursue for, guiding our lifecycle management strategy with data-driven confidence.”
SVP, Strategy & Portfolio Management
“PhaseV’s Portfolio Optimizer allowed us to draw clear, data-driven connections between biomarkers and clinical outcomes. This deeper understanding of therapeutic relevance has been critical in shaping our development strategy and informing key decisions for future studies, including those with combination arms.”
VP of Biometrics
“Through our initial collaboration with PhaseV, we gained an even greater understanding of the effect of PrimeC across multiple patient subgroups. We will apply these insights to optimize the design of our Phase 3 study. We plan to continue to collaborate with PhaseV as we develop our Phase 3 trial.”
NeuroSense
“PhaseV played a vital role in the analysis of our Phase 3 trial in the US, ORA-D-013-1, for the treatment of type 2 diabetes. The analysis found subpopulations of patients that responded very well to oral insulin.”
Dr. Miriam Kidron
“Combining our GI expertise with PhaseV’s advanced machine learning capabilities for trial simulation, design, and execution accelerates success for our sponsors and help address the growing burden of GI diseases more effectively.”
Pierre Gaudreault
“The addition of prospectively collected clinical-grade real world data to phase 2 result in conjunction with PhaseV’s proven technology is a critical step forward in improving phase 3 oncology trials, helping to bring new therapies to market.”
Michael Pröschel

VP, Clinical Operations
SVP, Strategy & Portfolio Management
VP of Biometrics









